RU2688168C2 - Прогнозирование исходов у пациентов с хронической обструктивной болезнью легких - Google Patents
Прогнозирование исходов у пациентов с хронической обструктивной болезнью легких Download PDFInfo
- Publication number
- RU2688168C2 RU2688168C2 RU2014140608A RU2014140608A RU2688168C2 RU 2688168 C2 RU2688168 C2 RU 2688168C2 RU 2014140608 A RU2014140608 A RU 2014140608A RU 2014140608 A RU2014140608 A RU 2014140608A RU 2688168 C2 RU2688168 C2 RU 2688168C2
- Authority
- RU
- Russia
- Prior art keywords
- score
- years
- patients
- copd
- parameters
- Prior art date
Links
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title claims abstract description 100
- 239000000090 biomarker Substances 0.000 claims abstract description 58
- 108010048233 Procalcitonin Proteins 0.000 claims abstract description 49
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 claims abstract description 48
- 230000005540 biological transmission Effects 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 28
- 150000001413 amino acids Chemical class 0.000 claims abstract description 26
- 239000012634 fragment Substances 0.000 claims abstract description 25
- 239000002243 precursor Substances 0.000 claims abstract description 17
- 101800001288 Atrial natriuretic factor Proteins 0.000 claims abstract description 10
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 claims abstract description 9
- 101800001890 Atrial natriuretic peptide Proteins 0.000 claims abstract description 8
- 210000002966 serum Anatomy 0.000 claims abstract description 8
- 210000004369 blood Anatomy 0.000 claims abstract description 6
- 239000008280 blood Substances 0.000 claims abstract description 6
- 210000002381 plasma Anatomy 0.000 claims abstract description 6
- 206010036790 Productive cough Diseases 0.000 claims abstract description 5
- 208000024794 sputum Diseases 0.000 claims abstract description 5
- 210000003802 sputum Anatomy 0.000 claims abstract description 5
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 claims abstract description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims abstract description 4
- 210000003296 saliva Anatomy 0.000 claims abstract description 4
- 210000002700 urine Anatomy 0.000 claims abstract description 4
- 208000002151 Pleural effusion Diseases 0.000 claims abstract description 3
- 102400000060 Copeptin Human genes 0.000 claims description 21
- 101800000115 Copeptin Proteins 0.000 claims description 21
- 208000000059 Dyspnea Diseases 0.000 claims description 14
- 206010013975 Dyspnoeas Diseases 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 208000000884 Airway Obstruction Diseases 0.000 claims description 8
- 230000009798 acute exacerbation Effects 0.000 claims description 8
- 239000003550 marker Substances 0.000 abstract description 21
- 239000003814 drug Substances 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 26
- 230000004083 survival effect Effects 0.000 description 23
- 108090000765 processed proteins & peptides Proteins 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 18
- 238000012360 testing method Methods 0.000 description 13
- 239000000975 dye Substances 0.000 description 12
- 102000034567 proadrenomedullin Human genes 0.000 description 12
- 108010012004 proadrenomedullin Proteins 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 11
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 10
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 10
- 210000000038 chest Anatomy 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 9
- 125000000539 amino acid group Chemical group 0.000 description 9
- 238000012544 monitoring process Methods 0.000 description 8
- 238000012502 risk assessment Methods 0.000 description 8
- 230000027455 binding Effects 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 102100034296 Natriuretic peptides A Human genes 0.000 description 6
- 101710187800 Natriuretic peptides A Proteins 0.000 description 6
- 230000005713 exacerbation Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 5
- 238000002834 transmittance Methods 0.000 description 5
- 108010091794 preprovasopressin Proteins 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000002411 adverse Effects 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 239000013060 biological fluid Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 108020001621 Natriuretic Peptide Proteins 0.000 description 2
- 102000004571 Natriuretic peptide Human genes 0.000 description 2
- 102000002710 Neurophysins Human genes 0.000 description 2
- 108010018674 Neurophysins Proteins 0.000 description 2
- 108010004977 Vasopressins Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- GWQVMPWSEVRGPY-UHFFFAOYSA-N europium cryptate Chemical compound [Eu+3].N=1C2=CC=CC=1CN(CC=1N=C(C=CC=1)C=1N=C(C3)C=CC=1)CC(N=1)=CC(C(=O)NCCN)=CC=1C(N=1)=CC(C(=O)NCCN)=CC=1CN3CC1=CC=CC2=N1 GWQVMPWSEVRGPY-UHFFFAOYSA-N 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010324 immunological assay Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000004199 lung function Effects 0.000 description 2
- 239000000692 natriuretic peptide Substances 0.000 description 2
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 108010049361 preproadrenomedullin Proteins 0.000 description 2
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 229910052761 rare earth metal Inorganic materials 0.000 description 2
- 150000002910 rare earth metals Chemical class 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 238000013125 spirometry Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- WQZIDRAQTRIQDX-UHFFFAOYSA-N 6-carboxy-x-rhodamine Chemical compound OC(=O)C1=CC=C(C([O-])=O)C=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 WQZIDRAQTRIQDX-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102400000686 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- 102400000112 Katacalcin Human genes 0.000 description 1
- 101800003632 Katacalcin Proteins 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 102400001263 NT-proBNP Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- -1 Texas Red Chemical compound 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 239000000999 acridine dye Substances 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- JXSBZDNBNJTHBJ-JPZUGYNPSA-M carfecillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)C(C=1C=CC=CC=1)C(=O)OC1=CC=CC=C1 JXSBZDNBNJTHBJ-JPZUGYNPSA-M 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000028659 discharge Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- BOARIOLZPFSAQJ-NQSKQZERSA-N katacalcin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](OC)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)C(CC=1NC=NC=1)NC(=O)C(CC(O)=O)NC(=O)C(CCCNC(N)=N)NC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)C(CO)NC(=O)C(CCSC)NC(=O)[C@@H](N)CC(O)=O)C1=CN=CN1 BOARIOLZPFSAQJ-NQSKQZERSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000013123 lung function test Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- BABRMHJHAGFVGO-BRTFOEFASA-N peptide, atrial natriuretic Chemical compound C([C@@H](C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CS)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C1=CC=CC=C1 BABRMHJHAGFVGO-BRTFOEFASA-N 0.000 description 1
- 150000005053 phenanthridines Chemical class 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000011947 six minute walk test Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/585—Calcitonins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12001590.4A EP2637023A1 (en) | 2012-03-08 | 2012-03-08 | Prediction of outcome in patients with chronic obstructive pulmonary disease |
| EP12001590.4 | 2012-03-08 | ||
| PCT/EP2013/000558 WO2013131621A1 (en) | 2012-03-08 | 2013-02-26 | Prediction of outcome in patients with chronic obstructive pulmonary disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2014140608A RU2014140608A (ru) | 2016-04-27 |
| RU2688168C2 true RU2688168C2 (ru) | 2019-05-20 |
Family
ID=47780019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014140608A RU2688168C2 (ru) | 2012-03-08 | 2013-02-26 | Прогнозирование исходов у пациентов с хронической обструктивной болезнью легких |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150080246A1 (cg-RX-API-DMAC7.html) |
| EP (3) | EP2637023A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6117251B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104126125B (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014019349A8 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2823314T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2631653T3 (cg-RX-API-DMAC7.html) |
| IN (1) | IN2014DN07813A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2688168C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013131621A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201405610B (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2795193C1 (ru) * | 2021-11-26 | 2023-05-02 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Чувашский государственный университет имени И. Н. Ульянова" | Способ раннего прогнозирования отдаленного исхода хронической обструктивной болезни легких. |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2812700B1 (en) | 2012-02-09 | 2018-04-18 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections and methods of use thereof |
| EP2637023A1 (en) | 2012-03-08 | 2013-09-11 | B.R.A.H.M.S GmbH | Prediction of outcome in patients with chronic obstructive pulmonary disease |
| JP6661607B2 (ja) | 2014-08-14 | 2020-03-11 | メメド ダイアグノスティクス リミテッド | 多様体および超平面を用いる生物学的データのコンピュータ分析 |
| WO2016075054A1 (en) * | 2014-11-12 | 2016-05-19 | Koninklijke Philips N.V. | Apparatus and method for assessing the severity of chronic obstructive pulmonary disease, copd, in a subject |
| WO2016092554A1 (en) | 2014-12-11 | 2016-06-16 | Memed Diagnostics Ltd. | Marker combinations for diagnosing infections and methods of use thereof |
| CA2986097A1 (en) * | 2015-05-18 | 2016-11-24 | The University Of British Columbia | Methods and systems of detecting plasma protein biomarkers for diagnosing acute exacerbation of copd |
| CN108699583B (zh) | 2016-03-03 | 2022-11-01 | 米密德诊断学有限公司 | 用于区分细菌和病毒感染的rna决定子 |
| CN107229813A (zh) * | 2016-03-24 | 2017-10-03 | 深圳中迈数字医疗技术有限公司 | 实施监护的判断方法及系统 |
| CN109804245B (zh) | 2016-07-10 | 2022-10-25 | 米密德诊断学有限公司 | 感染的早期诊断 |
| EP3482200B1 (en) | 2016-07-10 | 2022-05-04 | Memed Diagnostics Ltd. | Protein signatures for distinguishing between bacterial and viral infections |
| EP3519834A4 (en) * | 2016-09-29 | 2020-06-17 | MeMed Diagnostics Ltd. | RISK ASSESSMENT AND DISEASE CLASSIFICATION METHODS |
| US11385241B2 (en) | 2016-09-29 | 2022-07-12 | Memed Diagnostics Ltd. | Methods of prognosis and treatment |
| CN110431425B (zh) * | 2017-02-02 | 2023-06-27 | B.R.A.H.M.S 有限公司 | proADM作为指示不良事件的标志物 |
| EP3610260A4 (en) * | 2017-04-12 | 2021-01-06 | ProterixBio, Inc. | COMBINATIONS OF BIOMARKERS TO MONITOR CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY AND / OR ASSOCIATED MECHANISMS |
| CN107267658B (zh) * | 2017-08-21 | 2018-11-02 | 常州市第二人民医院 | Copd诊断用分子标志物 |
| WO2019053124A1 (en) * | 2017-09-13 | 2019-03-21 | B.R.A.H.M.S Gmbh | PROADRENOMEDULINE AS AN INDICATOR FOR RENAL REPLACEMENT THERAPY IN SERIOUSLY PATIENT PATIENTS |
| EP3682246A1 (en) * | 2017-09-13 | 2020-07-22 | B.R.A.H.M.S GmbH | Method for guidance of fluid therapy based on proadrenomedullin |
| US20200264199A1 (en) * | 2017-09-13 | 2020-08-20 | B.R.A.H.M.S Gmbh | Pct and pro-adm as markers for monitoring antibiotic treatment |
| EP3502706A1 (en) * | 2017-12-20 | 2019-06-26 | B.R.A.H.M.S GmbH | Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin |
| CN108424969B (zh) * | 2018-06-06 | 2022-07-15 | 深圳市颐康生物科技有限公司 | 一种生物标志物、诊断或预估死亡风险的方法 |
| CN109218131B (zh) * | 2018-09-03 | 2022-03-29 | 平安医疗健康管理股份有限公司 | 网络监控方法、装置、计算机设备和存储介质 |
| WO2020169799A1 (en) * | 2019-02-21 | 2020-08-27 | B.R.A.H.M.S Gmbh | Method for the diagnosis of macce in patients who underwent gastrointestinal surgery |
| FR3094491B1 (fr) * | 2019-03-28 | 2024-07-19 | Rheonova | Méthode in vitro de diagnostic, de stratification, de pronostic et/ou de suivi d'une maladie des poumons et/ou une maladie respiratoire |
| CN110850006B (zh) * | 2019-12-20 | 2020-11-20 | 河南中医药大学 | 一种慢性阻塞性肺病诊断试剂及试剂盒 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| DK2019965T3 (en) * | 2006-05-02 | 2015-07-20 | Critical Care Diagnostics Inc | DIFFERENTIAL BETWEEN LUNG AND Cardiovascular Disease |
| DE102006046996A1 (de) * | 2006-10-01 | 2008-04-03 | Brahms Aktiengesellschaft | Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz |
| DE102006053442A1 (de) * | 2006-11-12 | 2008-05-15 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II |
| DE102006060112A1 (de) * | 2006-12-20 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM |
| US8815519B2 (en) * | 2006-12-22 | 2014-08-26 | Hvidovre Hospital | Method for predicting cancer and other diseases |
| DE102007021443A1 (de) * | 2007-05-08 | 2008-11-13 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels NT-proET-1 |
| PT2269063E (pt) * | 2008-04-18 | 2013-11-27 | Critical Care Diagnostics Inc | Predição do risco de eventos cardíacos adversos maiores |
| WO2010054810A1 (en) * | 2008-11-11 | 2010-05-20 | B.R.A.H.M.S Ag | Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm and bnp |
| GB0911007D0 (en) * | 2009-06-25 | 2009-08-12 | Univ Hospital Of North Staffordshire | Analyzer apparatus and methods for lung disease |
| CN102253220B (zh) * | 2011-06-07 | 2014-04-09 | 复旦大学附属中山医院 | 用于诊断慢性阻塞性肺病急性加重期的试剂盒 |
| EP2637023A1 (en) | 2012-03-08 | 2013-09-11 | B.R.A.H.M.S GmbH | Prediction of outcome in patients with chronic obstructive pulmonary disease |
-
2012
- 2012-03-08 EP EP12001590.4A patent/EP2637023A1/en not_active Withdrawn
-
2013
- 2013-02-26 EP EP17000604.3A patent/EP3232201A1/en active Pending
- 2013-02-26 CN CN201380009139.6A patent/CN104126125B/zh active Active
- 2013-02-26 US US14/383,744 patent/US20150080246A1/en not_active Abandoned
- 2013-02-26 EP EP13707113.0A patent/EP2823314B1/en not_active Revoked
- 2013-02-26 WO PCT/EP2013/000558 patent/WO2013131621A1/en not_active Ceased
- 2013-02-26 ES ES13707113.0T patent/ES2631653T3/es active Active
- 2013-02-26 JP JP2014560266A patent/JP6117251B2/ja active Active
- 2013-02-26 DK DK13707113.0T patent/DK2823314T3/en active
- 2013-02-26 IN IN7813DEN2014 patent/IN2014DN07813A/en unknown
- 2013-02-26 RU RU2014140608A patent/RU2688168C2/ru active
- 2013-02-26 BR BR112014019349A patent/BR112014019349A8/pt not_active Application Discontinuation
-
2014
- 2014-07-29 ZA ZA2014/05610A patent/ZA201405610B/en unknown
Non-Patent Citations (3)
| Title |
|---|
| GOKMEN GEMICI B-type natriuretic peptide lavals in patients with COPD and Normal Right ventricular function// Adv Ther, 2008, 25(7), 674-680. * |
| LACOMA A. et al. Biomarkers in the management of COPD. Eur Respir Rev, 2009, 18, 12, р.96-104. SU YOUNG CHI et al. Plasma N-terminal pro-brain natriuretic peptide: a prognostic marker in patients with chronic ostructive pulmonary disease // LUNG (2012) 190: 271-276. * |
| LACOMA A. et al. Biomarkers in the management of COPD. Eur Respir Rev, 2009, 18, 12, р.96-104. SU YOUNG CHI et al. Plasma N-terminal pro-brain natriuretic peptide: a prognostic marker in patients with chronic ostructive pulmonary disease // LUNG (2012) 190: 271-276. GOKMEN GEMICI B-type natriuretic peptide lavals in patients with COPD and Normal Right ventricular function// Adv Ther, 2008, 25(7), 674-680. * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2795193C1 (ru) * | 2021-11-26 | 2023-05-02 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Чувашский государственный университет имени И. Н. Ульянова" | Способ раннего прогнозирования отдаленного исхода хронической обструктивной болезни легких. |
| RU2811937C1 (ru) * | 2023-01-24 | 2024-01-18 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации | Способ прогнозирования смертельного исхода у пациентов с хронической обструктивной болезнью легких |
| RU2838312C1 (ru) * | 2024-08-06 | 2025-04-14 | федеральное государственное бюджетное образовательное учреждение высшего образования "Ульяновский государственный университет" | Способ прогнозирования риска развития затяжного плеврального выпота после анатомических резекций легкого |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201405610B (en) | 2015-12-23 |
| CN104126125A (zh) | 2014-10-29 |
| CN104126125B (zh) | 2017-03-01 |
| IN2014DN07813A (cg-RX-API-DMAC7.html) | 2015-07-10 |
| JP6117251B2 (ja) | 2017-04-19 |
| EP2823314A1 (en) | 2015-01-14 |
| EP2637023A1 (en) | 2013-09-11 |
| HK1198556A1 (en) | 2015-05-15 |
| WO2013131621A8 (en) | 2014-06-12 |
| BR112014019349A2 (cg-RX-API-DMAC7.html) | 2017-06-20 |
| DK2823314T3 (en) | 2017-07-03 |
| EP2823314B1 (en) | 2017-04-12 |
| RU2014140608A (ru) | 2016-04-27 |
| JP2015509596A (ja) | 2015-03-30 |
| ES2631653T3 (es) | 2017-09-01 |
| BR112014019349A8 (pt) | 2017-07-11 |
| EP3232201A1 (en) | 2017-10-18 |
| WO2013131621A1 (en) | 2013-09-12 |
| US20150080246A1 (en) | 2015-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2688168C2 (ru) | Прогнозирование исходов у пациентов с хронической обструктивной болезнью легких | |
| CN102317790B (zh) | Adm在制备用于评估心力衰竭和/或呼吸短促的制剂中的应用 | |
| CN104303061B (zh) | 患有疑似慢性心力衰竭的患者中不良事件的预后 | |
| JP5890427B2 (ja) | 非特異的症状を有する患者の予後及びリスク評価 | |
| CN102105794A (zh) | 移植物衰竭和死亡的标志物 | |
| CN107064516B (zh) | 用于诊断中风的nt-原anp和nt-原bnp | |
| US20160245827A1 (en) | L-fabp based diagnosis of kidney injury after an acute event or after a surgical intervention | |
| JP7194673B2 (ja) | 臓器障害を示すマーカーとしてのヒストンおよび／またはｐｒｏＡＤＭ | |
| JP2020034564A (ja) | 心不全リスクの予測改善のためのバイオマーカー | |
| US20210311074A1 (en) | Method for obtaining information on risk of reduced respiratory function in patient with interstitial pneumonia | |
| US20150093814A1 (en) | System, an apparatus and a computer program product for obtaining an information related to eosinophilic airway inflammation | |
| EP2511704A1 (en) | Assay method for intrinsic acute kidney injury | |
| US20170016914A1 (en) | Nephropathy biomarker | |
| HK1198556B (en) | Prediction of outcome in patients with chronic obstructive pulmonary disease | |
| HK1203611B (en) | Prognosis of adverse events in patients with suspected chronic heart failure | |
| HK1163813B (en) | Use of adm in manufacturing an agent for evaluating heart failure and/or shortness of breath | |
| HK1187101A (en) | Prognosis and risk assessment of patients with non-specific complaints | |
| HK1187101B (en) | Prognosis and risk assessment of patients with non-specific complaints |